APT-modified biomimetic ROS-responsive nanocarrier (NP-APT) loaded with dimethyl fumarate enhances myocardial delivery, ameliorates diabetic cardiomyopathy, and restores autophagy-apoptosis balance in association with Mst1 pathway modulation.
Key Findings
Results
NP-APT demonstrated favorable physicochemical properties including ROS-responsive drug release, serum/storage stability, and macrophage-avoidance capability.
The nanoplatform comprises a ROS-sensitive core and a lipid-cell membrane hybrid coating modified with cardiac-targeting peptide (APT)
ROS-responsive release mechanism allows context-specific drug delivery in oxidative stress environments characteristic of diabetic cardiomyopathy
Macrophage-avoidance capability was demonstrated, suggesting reduced immune clearance
Serum and storage stability were confirmed as favorable physicochemical properties
Results
NP-APT enhanced cardiomyocyte uptake and mitigated high-glucose-induced oxidative stress in vitro.
In vitro studies used high-glucose conditions to model diabetic cardiomyopathy
APT modification was associated with enhanced cardiomyocyte uptake compared to unmodified formulations
NP-APT mitigated high-glucose-induced oxidative stress in cardiomyocytes
Treatment restored mitochondrial function and bioenergetic activity
Apoptosis was attenuated in cardiomyocytes treated with NP-APT under high-glucose conditions
Results
NP-APT protected cardiomyocytes in association with reduced Mst1-related protein abundance and improved autophagy-related signaling.
Mechanistic studies showed reduced Mst1-related protein abundance following NP-APT treatment
Improved autophagy-related signaling was observed in association with NP-APT treatment
The autophagy-apoptosis equilibrium was rebalanced by NP-APT treatment
Mst1 overexpression weakened the protective effects of NP-APT, confirming pathway involvement
Autophagy blockade reduced NP-APT-mediated protection, indicating autophagy is required for the observed effects
Results
In a murine DCM model, NP-APT achieved cardiac-specific accumulation and significantly improved cardiac function and fibrosis.
A murine diabetic cardiomyopathy model was used for in vivo studies
NP-APT demonstrated cardiac-specific accumulation attributed to APT targeting
Cardiac function was significantly improved compared to controls
Cardiac fibrosis was reduced following NP-APT treatment
Cellular homeostasis was restored, with efficacy associated with Mst1 pathway modulation
Results
NP-APT did not produce evident additional systemic toxicity under the tested treatment conditions in DCM mice.
Safety was assessed via hematological, biochemical, behavioral, and histological evaluations
No evident additional systemic toxicity was observed in DCM mice under the tested conditions
Safety assessments were conducted as part of in vivo studies in the murine DCM model
The authors specify findings apply to 'tested treatment conditions,' indicating results are condition-specific
Background
Dimethyl fumarate (DMF) was selected as the therapeutic cargo based on its known NRF2-activating redox modulation properties.
DMF is described as 'a known NRF2-activating redox modulator'
The nanoplatform was developed specifically to improve myocardial delivery of DMF
NRF2 activation is relevant to oxidative stress mitigation in diabetic cardiomyopathy
DMF encapsulation in the ROS-responsive nanocarrier allows targeted release in high-oxidative-stress cardiac environments
Background
Diabetic cardiomyopathy pathology is driven by oxidative stress and an imbalance between autophagy and apoptosis.
The study identifies oxidative stress as a primary driver of DCM
An imbalance between autophagy and apoptosis is identified as a key mechanistic feature of DCM
The Mst1 pathway is implicated in regulating the autophagy-apoptosis balance in this context
Restoring this balance is presented as the central therapeutic rationale for the nanoplatform design
What This Means
This research suggests that a specially engineered drug delivery nanoparticle can effectively treat diabetic cardiomyopathy (heart disease caused by diabetes) by targeting the heart and releasing a therapeutic drug precisely where oxidative stress is highest. The nanoparticle — called NP-APT — is coated with a heart-targeting peptide and a biological membrane that helps it avoid immune clearance, and it carries dimethyl fumarate, a drug known to combat oxidative stress. The particle only releases its drug payload when it detects high levels of reactive oxygen species (ROS), which are chemical byproducts of oxidative stress that are elevated in the diabetic heart. In laboratory and animal experiments, this system delivered drug specifically to heart tissue, reduced oxidative damage, and improved heart function and scarring (fibrosis).
The study also uncovered a key biological mechanism behind the therapy's effectiveness. NP-APT works by reducing the activity of a protein called Mst1, which in turn restores the balance between two cellular processes — autophagy (the cell's self-cleaning mechanism) and apoptosis (programmed cell death). In diabetic cardiomyopathy, this balance is disrupted, causing excessive cell death. When researchers artificially increased Mst1 levels, the protective effects of NP-APT were diminished; when they blocked autophagy, protection was also reduced — confirming that both the Mst1 pathway and autophagy are necessary for the treatment to work.
This research suggests that combining targeted nanoparticle delivery with a drug that modulates oxidative stress and cellular survival pathways may represent a promising strategy for treating diabetic heart disease. The nanoparticle system showed no apparent additional toxicity in diabetic mice under the tested conditions, suggesting a reasonable safety profile, though further studies would be needed before any clinical application. The findings highlight that restoring the balance between cell survival and cell death processes — through precise drug delivery — could be an important approach for managing heart complications in diabetes.
Li X, Li G, Meng N, Xu W, Tang R, Chen J, et al.. (2026). Restoring autophagy-apoptosis balance in diabetic cardiomyopathy via a biomimetic, ROS-responsive nanocarrier associated with Mst1 pathway modulation.. Journal of nanobiotechnology. https://doi.org/10.1186/s12951-026-04903-3